Search Results
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
lead to death Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. NMS can cause death and must be treated in a hospital. Call your healthcare
More news about: Johnson & Johnson
Aug 27, 2026, 09:00 ET RQD* Clearing Secures $74 Million Strategic Growth Investment Led by Bain Capital
approximately 515 million equity transactions, representing 69.5 billion shares, nearly $2 trillion in notional value and approximately 2.43% of the NMS equities market. During the same period, RQD* cleared nearly 64.8 million options contracts, representing $120.7 billion in premium and $3.93 trillion
More news about: RQD* Clearing
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint. Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
Jul 28, 2026, 08:49 ET Birdai Labs Raises $4 Million to Return Onchain Trading Value to the People Who Create It
Scanlon.Traditional markets earned institutional participation by making execution quality measurable and enforceable, through frameworks like Regulation NMS and order-handling disclosure. The rules for digital assets are still being written. What is not in doubt is what institutions will require before they
More news about: Birdai Labs
Jul 23, 2026, 09:30 ET Ondo Finance's Oasis Pro Markets Secures FINRA Authorizations to Offer Broad Range of Tokenized Equities and Funds to U.S. Investors
engage in secondary trading of, these tokenized securities. Under this framework, Oasis Pro Markets can offer U.S. investors market access to NMS equities, fund interests such as ETFs, mutual funds, and index funds, and securities issued through IPOs and traded in secondary markets. Settlement
More news about: Ondo Finance
Jul 20, 2026, 16:45 ET Cardinal Health expands home care business with two tuck-in acquisitions
commercial insurance plans and reaches millions of patients annually.About Strive Medical LLCStrive Medical, an NMS Capital portfolio company, is a leading national durable medical equipment (DME) provider specializing in urology, incontinence, and wound care supplies
More news about: Cardinal Health
Jul 09, 2026, 12:39 ET Ekinops announces Q2 2026 revenue of €30.6m
(reconfigurable optical add-drop multiplexers) for Proximus' backbone and metro networks. Ekinops will also provide its network management solution, Celestis NMS, together with associated software and professional services, to support Proximus in building its next-generation, high-performance optical network.Following
More news about: Ekinops
Jul 08, 2026, 10:31 ET Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight
in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NMS companies, including Johnson & Johnson (Janssen Pharmaceuticals), AstraZeneca, Eli Lilly and Company, Pfizer, Novartis, GlaxoSmithKline, Bristol
More news about: DelveInsight Business Research, LLP
Jul 07, 2026, 17:30 ET SIPs Receive SEC Approval for Extended Trading Hours Initiative
(https://www.sec.gov/files/rules/sro/nms/2026/34-105779.pdf)
More news about: SIP Operating Committees
Jul 06, 2026, 13:14 ET Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices
www.dcmbio.com.About NMS Capital:Founded in 2010, NMS Capital is an experienced private equity firm managing assets in excess of $2.0 billion. Since inception, NMS has partnered with management teams in over 150 investments and follow-on
More news about: DCM BioServices
Jul 02, 2026, 01:30 ET Ekinops Announces Framework Agreement with Proximus to deploy a nationwide high-speed optical network across Belgium
(reconfigurable optical add-drop multiplexers) for Proximus' backbone and metro networks. Ekinops will also provide its network management solution, Celestis NMS, together with associated software and professional services, to support Proximus in building its next-generation, high-performance optical network."We
More news about: Ekinops
Jun 25, 2026, 17:30 ET Akemona Launches CapMark™ AI Agent as Part of Its AI Investment Banker Platform
currently advancing a landmark shift for tokenization by exploring an Innovation Exemption—including the proposed repeal of core Regulation NMS rules—to permit third parties to tokenize U.S. stocks without issuer approval, paving the way for 24/7 global trading on blockchain rails. This regulatory
More news about: Akemona, Inc.
Jun 08, 2026, 16:05 ET Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
Jun 08, 2026, 08:30 ET Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
May 19, 2026, 18:14 ET BLUE OCEAN TECHNOLOGIES APPOINTS WILLIAM GOODBODY, JR. AS HEAD OF MARKET OPERATIONS FOR BLUE OCEAN ATS IN AUSTRALIA
trading hours. Blue Ocean ATS, LLC, and its trading system Blue Ocean Alternative Trading System (BOATS), currently trade US National Market System (NMS) stocks from 8:00 pm to 4:00 am ET from Sunday – Thursday. Founded in 2019, Blue Ocean ATS is on a mission to transform US trading to Global trading
More news about: Blue Ocean Technologies, LLC
May 18, 2026, 16:05 ET Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
May 11, 2026, 08:00 ET Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
lead to death Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. NMS can cause death and must be treated in a hospital. Call your healthcare
More news about: Johnson & Johnson
May 05, 2026, 09:00 ET Securitize, Jump Trading Group, and Jupiter Launch Fully Onchain, Regulated Trading for Tokenized Equities
Xiao-Xiao, President of Jupiter. Importantly, the system is designed to operate within existing regulatory frameworks, including Regulation NMS. Securitize enables tokenized equities to scale in line with established market structure rules while benefiting from the efficiencies of blockchain-based
More news about: Securitize
May 04, 2026, 08:00 ET CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
(cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death.Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of
More news about: Johnson & Johnson
Apr 29, 2026, 16:05 ET Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
Apr 27, 2026, 08:00 ET FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
(cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death.Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of
More news about: Johnson & Johnson
Apr 14, 2026, 08:30 ET Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
Apr 02, 2026, 09:00 ET NATIONAL MARINE SANCTUARY FOUNDATION CELEBRATES ROBUST SECOND ROUND OF SANCTUARY COMMUNITY FUND GRANTEES
FORCE BLUE (Chumash Heritage and Lake Ontario NMS) Project Name: "FORCE BLUE'S 2026 National Marine Sanctuaries Tour of Duty"Marine Technology Society, Inc (Lake Ontario and Papahānaumokuākea NMS)Project Name: Building Community and Capacity
More news about: National Marine Sanctuary Foundation
Mar 26, 2026, 08:30 ET Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms
More news about: Neurocrine Biosciences, Inc.
Mar 19, 2026, 11:23 ET Home Telecom Completes High-Split HFC Modernization with Teleste and Mega Hertz
Deployment of Teleste ICON intelligent amplifiers and Argus NMS strengthens reliability, improves operational visibility, and prepares the network for DOCSIS 4.0 evolution.TURKU, Finland, March 19, 2026 /PRNewswire/
More news about: Teleste Corporation